BidaskClub Lowers Amicus Therapeutics (FOLD) to Strong Sell
BidaskClub cut shares of Amicus Therapeutics (NASDAQ:FOLD) from a sell rating to a strong sell rating in a research note released on Saturday morning.
FOLD has been the topic of several other research reports. ValuEngine raised shares of Amicus Therapeutics from a buy rating to a strong-buy rating in a report on Friday, August 10th. Zacks Investment Research raised shares of Amicus Therapeutics from a hold rating to a buy rating and set a $18.00 price target on the stock in a report on Tuesday, July 10th. Chardan Capital cut shares of Amicus Therapeutics from a buy rating to a neutral rating and decreased their price target for the stock from $18.00 to $15.00 in a report on Friday. Finally, Cowen reaffirmed a buy rating and issued a $22.00 price target on shares of Amicus Therapeutics in a report on Tuesday, May 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of Buy and an average price target of $19.43.
Amicus Therapeutics stock opened at $13.22 on Friday. The firm has a market capitalization of $2.90 billion, a PE ratio of -4.53 and a beta of 1.34. Amicus Therapeutics has a fifty-two week low of $12.04 and a fifty-two week high of $17.62. The company has a current ratio of 10.88, a quick ratio of 10.73 and a debt-to-equity ratio of 0.30.
In related news, insider Hung Do sold 25,000 shares of the company’s stock in a transaction on Friday, June 1st. The shares were sold at an average price of $16.72, for a total value of $418,000.00. Following the completion of the transaction, the insider now directly owns 396,771 shares in the company, valued at $6,634,011.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Kurt J. Andrews sold 5,000 shares of the company’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $15.63, for a total transaction of $78,150.00. Following the completion of the transaction, the senior vice president now owns 40,469 shares of the company’s stock, valued at $632,530.47. The disclosure for this sale can be found here. Insiders sold 40,000 shares of company stock valued at $652,450 over the last quarter. 2.90% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the stock. Exane Derivatives purchased a new position in Amicus Therapeutics in the second quarter worth $137,000. Arbor Wealth Management LLC purchased a new position in Amicus Therapeutics in the second quarter worth $144,000. P.R. Herzig & Co. Inc. purchased a new position in Amicus Therapeutics in the second quarter worth $156,000. Quantitative Systematic Strategies LLC purchased a new position in Amicus Therapeutics in the second quarter worth $179,000. Finally, Palisade Capital Management LLC NJ purchased a new position in Amicus Therapeutics in the first quarter worth $211,000.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Read More: Trading Penny Stocks
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.